Recombinant Human GPAT3 Protein, N-His from ProteoGenix; catalogue ARO-P12084; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant proteins are proteins that are produced through genetic engineering techniques, where the gene for a specific protein is inserted into a host cell and then expressed to produce large quantities of the desired protein. These proteins have become essential tools in various fields of research, diagnostics, and therapeutics. One such recombinant protein is the human GPAT3 protein, which has gained significant interest due to its role in lipid metabolism and its potential as a therapeutic target for various diseases.
The human GPAT3 protein, also known as glycerol-3-phosphate acyltransferase 3, is an enzyme that plays a crucial role in the biosynthesis of triacylglycerol (TAG), the main storage form of fat in the body. The recombinant human GPAT3 protein is composed of 372 amino acids and has a molecular weight of approximately 41 kDa. It contains a conserved catalytic domain, which is responsible for its enzymatic activity, and a transmembrane domain, which anchors the protein to the endoplasmic reticulum membrane.
The main function of the recombinant human GPAT3 protein is to catalyze the first step in the synthesis of TAG, which involves the transfer of an acyl group from acyl-CoA to glycerol-3-phosphate. This reaction is essential for the production of TAG, which is a vital component of cell membranes and a major source of energy in the body. Additionally, GPAT3 has been shown to play a role in regulating lipid metabolism and insulin sensitivity, making it a potential therapeutic target for metabolic disorders such as obesity and diabetes.
The recombinant human GPAT3 protein has a wide range of applications in both research and medicine. In research, it is used as a tool to study the role of GPAT3 in lipid metabolism and to investigate its potential as a therapeutic target. It is also used in drug discovery and development, as compounds that can modulate GPAT3 activity may have therapeutic benefits for metabolic disorders.
In medicine, the recombinant human GPAT3 protein has potential applications in the treatment of metabolic disorders. For instance, studies have shown that inhibiting GPAT3 activity can improve insulin sensitivity and reduce fat accumulation in animal models of obesity and diabetes. Therefore, the recombinant protein may be used in the development of new drugs for these conditions. Additionally, GPAT3 may also have a role in cancer, as it has been found to be overexpressed in certain types of tumors, making it a potential target for cancer therapy.
The recombinant human GPAT3 protein is a versatile tool with important roles in lipid metabolism and potential applications in various fields. Its structure and activity have been extensively studied, and it has shown promising results as a therapeutic target for metabolic disorders and cancer. Further research on this protein may lead to the development of new treatments for these diseases, making it an exciting area of study in the field of recombinant proteins.
ProteoGenix catalogue number ARO-P12084. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 28.01 kDa; Fragment: Ser207-Ser434; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
